How big is Mesa Laboratories, Inc.?

As of Jun 18, Mesa Laboratories, Inc. has a market capitalization of 505.88 million and reported net sales of 240.97 million with a net profit of -1.97 million over the latest four quarters. Shareholder's funds are 159.83 million, and total assets amount to 433.35 million.

As of Jun 18, Mesa Laboratories, Inc. has a market capitalization of 505.88 million, classifying it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 240.97 million, while the sum of consolidated net profit for the same period is -1.97 million.<BR><BR>As of Mar 25, the shareholder's funds are reported at 159.83 million, and total assets amount to 433.35 million.

What does Mesa Laboratories, Inc. do?

Mesa Laboratories, Inc. designs and manufactures quality control products for the Pharmaceuticals & Biotechnology industry, with a market cap of approximately $505.88 million. As of March 2025, the company reported net sales of $62 million and a net loss of $7 million.

Overview: <BR>Mesa Laboratories, Inc. designs, manufactures, and markets quality control products and services in the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Sales: 62 Million (Quarterly Results - Mar 2025) <BR>Net Profit: -7 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 505.88 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.96 <BR>Return on Equity: -2.97% <BR>Price to Book: 3.17<BR><BR>Contact Details: <BR>Address: 12100 W 6th Ave, LAKEWOOD CO: 80228-1252 <BR>Tel: 1 303 9878000 <BR>Fax: 1 303 9878989 <BR>Website: https://mesalabs.com

Should I buy, sell or hold Mesa Laboratories, Inc.?

Who are in the management team of Mesa Laboratories, Inc.?

As of March 2022, the management team of Mesa Laboratories, Inc. includes Dr. John Sullivan (Chairman), Mr. Gary Owens (President and CEO), and several independent directors: Ms. Shannon Hall, Ms. Jennifer Alltoft, Mr. Evan Guillemin, Mr. David Kelly, and Mr. John Schmieder. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Mesa Laboratories, Inc. includes the following individuals:<BR><BR>- Dr. John Sullivan, Chairman of the Board<BR>- Mr. Gary Owens, President, Chief Executive Officer, and Director<BR>- Ms. Shannon Hall, Director<BR>- Ms. Jennifer Alltoft, Independent Director<BR>- Mr. Evan Guillemin, Independent Director<BR>- Mr. David Kelly, Independent Director<BR>- Mr. John Schmieder, Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Is Mesa Laboratories, Inc. overvalued or undervalued?

As of June 5, 2024, Mesa Laboratories, Inc. is considered overvalued with a risky valuation grade, reflected in its high Price to Book Value of 3.55 and EV to EBITDA of 17.66, alongside significant losses and a year-to-date stock performance decline of 47.55%.

As of 5 June 2024, Mesa Laboratories, Inc. has moved from a fair to risky valuation grade. The company appears to be overvalued, particularly given its significant losses reflected in the P/E ratio, which is not applicable due to the loss-making status. Key ratios include a Price to Book Value of 3.55, an EV to EBITDA of 17.66, and an EV to Sales of 2.99, all indicating a high valuation relative to its financial performance.<BR><BR>In comparison to peers, Mesa Laboratories has a notably high EV to EBITDA ratio compared to Atrion Corp. at 26.22, and a significantly worse P/E ratio than Silk Road Medical, Inc. at -19.76. The company's recent stock performance has been poor, with a year-to-date return of -47.55%, contrasting sharply with the S&P 500's positive return of 12.22% over the same period, further reinforcing the overvaluation narrative.

Is Mesa Laboratories, Inc. technically bullish or bearish?

As of July 1, 2025, Mesa Laboratories, Inc. is in a bearish trend, indicated by negative signals from MACD, moving averages, and KST, while significantly underperforming the S&P 500 with a year-to-date return of -47.55%.

As of 1 July 2025, the technical trend for Mesa Laboratories, Inc. has changed from mildly bearish to bearish. The current stance is bearish with a strong indication from multiple indicators: the MACD is bearish on both weekly and monthly time frames, moving averages are bearish on a daily basis, and the KST is bearish across both weekly and monthly periods. Additionally, Bollinger Bands and OBV show mildly bearish signals. The Dow Theory indicates a mildly bearish trend on the weekly chart, while the monthly chart shows no trend.<BR><BR>In terms of performance, the stock has significantly underperformed against the S&P 500, with a year-to-date return of -47.55% compared to the S&P 500's 12.22%, and a one-year return of -45.17% versus 17.14% for the benchmark.